{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-042955","form_type":"8-K","ticker":"IDXX","cik":"0000874716","company_name":"IDEXX LABORATORIES INC /DE","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.539843+00:00","generated_at":"2026-05-23T01:35:02.373598+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"IDEXX Q1 EPS $2.96 (+5%), rev $998M (+4%); raises FY25 revenue & EPS outlook","bullets":["Q1 revenue $998M (+4% reported, +5% organic); EPS $2.96 (+5%, +7% comparable).","CAG Diagnostics recurring revenue +3% reported, +4.5% organic; VetLab consumables organic +10%.","Launched IDEXX Cancer Dx for early canine lymphoma detection in North American reference labs.","FY25 revenue guidance raised to $4,095M-$4,210M; EPS guidance raised to $11.93-$12.43 ($0.19 increase).","FY25 organic revenue growth outlook maintained at 6%-9%; comparable EPS growth maintained at 8%-12%."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-042955","json":"https://secwatch.observer/filing/0001104659-25-042955.json","markdown":"https://secwatch.observer/filing/0001104659-25-042955.md","text":"https://secwatch.observer/filing/0001104659-25-042955.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874716/000110465925042955/0001104659-25-042955-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874716/000110465925042955/tm2513742d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T01:35:02.373598+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}